Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Willy Hugo

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Research Square|October 4, 2023
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma PatientsRichard G Everson, Willy Hugo, Lu Sun, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Nature Communications|June 5, 2024
Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialRichard G Everson, Willy Hugo, Lu Sun, et al.
Nature Communications|May 8, 2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialRichard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor EfficacyMelissa G Lechner, Mandy I Cheng, Anushi Y Patel, et al.
Cell Discovery|September 21, 2016
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanomaBjoern Titz, Anastasia Lomova, Allison Le, et al.
Nature Communications|November 27, 2021
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastomaAlexander H Lee, Lu Sun, Aaron Y Mochizuki, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
The Association of <i>MUC16</i> Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous MelanomaXuefeng Wang, Xiaoqing Yu, Michael Krauthammer, et al.
Nature Communications|May 23, 2014
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsAnna A Marusiak, Zoe C Edwards, Willy Hugo, et al.
Science Translational Medicine|May 17, 2023
Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditisMelissa G Lechner, Zikang Zhou, Aline T Hoang, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Research Square|October 4, 2023
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma PatientsRichard G Everson, Willy Hugo, Lu Sun, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Nature Communications|June 5, 2024
Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialRichard G Everson, Willy Hugo, Lu Sun, et al.
Nature Communications|May 8, 2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II TrialRichard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2022
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor EfficacyMelissa G Lechner, Mandy I Cheng, Anushi Y Patel, et al.
Cell Discovery|September 21, 2016
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanomaBjoern Titz, Anastasia Lomova, Allison Le, et al.
Nature Communications|November 27, 2021
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastomaAlexander H Lee, Lu Sun, Aaron Y Mochizuki, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
The Association of <i>MUC16</i> Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous MelanomaXuefeng Wang, Xiaoqing Yu, Michael Krauthammer, et al.
Nature Communications|May 23, 2014
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsAnna A Marusiak, Zoe C Edwards, Willy Hugo, et al.
Science Translational Medicine|May 17, 2023
Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditisMelissa G Lechner, Zikang Zhou, Aline T Hoang, et al.
Pageof 6